Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2020 Aug 7;109(1):288–297. doi: 10.1016/j.ijrobp.2020.08.017

Table 1.

Characterization of lesion variables by designated treatment

Lesions All n (%) SDRT n (%) PMDS n (%) SDRT vs PMDSP value SBRT n (%) PMDS vs SBRT P value
598 (100) 292 (49) 162 (27) 144 (24)
 Histology <.001 .029
  Prostate 143 (24) 84 (29) 36 (22) 23 (16)
  NSCLC 108 (18) 56 (19) 21 (13) 31 (22)
  CRC 86 (14) 43 (15) 24 (15) 19 (13)
  Breast 82 (14) 26 (9) 37 (23) 19 (13)
  Other 179 (30) 83 (28) 44 (27) 52 (36)
 Lesion site .06 <.001
 Bone 193 (32) 94 (32) 61 (38) 38 (27)
 Lymph nodes 212 (35) 81 (28) 47 (29) 84 (58)
 Liver 47 (8) 26 (9) 16 (10) 5 (3)
 Lung 105 (17) 70 (24) 26 (16) 9 (6)
 Soft tissues 47 (8) 27 (9) 12 (7) 8 (6)
Lesion volume <.001 .21
Median 5.1 4.8 6.1 7.5
Mean ± 1 SD 15.6 ± 37.8 7.9 ± 6.9 20.0 ± 36.9 27.6 ± 63.8
SUVmax .002 .81
Median 9.2 6.1 7.3 10.2
Mean ± 1 SD 6.8 ± 8.4 8.1 ± 12.9 10.4 ± 10.2 7.5 ± 8.7
Adjuvant treatment .76 .25
 Yes 335 (56) 158 (54) 99 (61) 78 (54)
 No 263 (44) 134 (46) 63 (39) 66 (46)

Abbreviations: adjuvant Tx = adjuvant systemic therapy; CRC = colorectal cancer; NSCLC = non-small cell lung cancer; PMDS = dose-sculpted SDRT coverage planned to a PTVPMDS subvolume to comply with radiation tolerance of an adjacent normal organ at risk (rest of the tumor treated with 24 Gy); SBRT = hypofractionated 3 × 9 Gy stereotactic body radiation therapy schedule; SD = standard deviation; SDRT = 24 Gy single-dose radiation therapy covering the whole tumor volume.